<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04381364</url>
  </required_header>
  <id_info>
    <org_study_id>2020-02183</org_study_id>
    <nct_id>NCT04381364</nct_id>
  </id_info>
  <brief_title>Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19)</brief_title>
  <acronym>HALT</acronym>
  <official_title>Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ola Blennow, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danderyd Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centrallasarettet Västerås</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St Goran's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized open label clinical trial carried out at study centers in Sweden, including
      Karolinska University Hospital Huddinge, S:t Göran Hospital, Danderyd Hospital and
      Västmanlands Hospital. Patients with COVID-19 who are hospitalized with oxygen therapy are
      eligible for inclusion. Subjects are randomized to 14 days of inhalation with ciclesonide 360
      µg twice daily or to standard of care. Primary outcome is time (in days) of received
      supplemental oxygen therapy. Key secondary outcome is a composite outcome of death and
      received invasive mechanical ventilation within 30 days.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 15, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This multicenter study is an open-labelled, randomized clinical trial for 1:1 ratio of ciclesonide or control arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of received supplemental oxygen therapy</measure>
    <time_frame>30 days after study inclusion</time_frame>
    <description>Time (in days) of received supplemental oxygen therapy (defined as being alive and discharged from hospital to home or at least 48 h of not receiving oxygen therapy during hospitalization).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Invasive mechanical ventilation or all-cause death</measure>
    <time_frame>30 days after study inclusion</time_frame>
    <description>Rate of and time to (in days) received invasive mechanical ventilation or all-cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause death</measure>
    <time_frame>30 days after study inclusion</time_frame>
    <description>Rate of and time to (in days) death of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invasive mechanical ventilation</measure>
    <time_frame>30 days after study inclusion</time_frame>
    <description>Rate of and time to (in days) received invasive mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum oxygen therapy</measure>
    <time_frame>30 days after study inclusion</time_frame>
    <description>Maximum received oxygen therapy during hospitalization in liters per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>30 days after study inclusion</time_frame>
    <description>Time (in days) from study inclusion to discharge from hospital.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remaining dyspnea symptoms</measure>
    <time_frame>3 and 6 months after inclusion. (Only for patients hospitalized at S:t Goran's Hospital)</time_frame>
    <description>Level of remaining dyspnea symptoms according to the Modified Medical Research Council Dyspnea Scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">446</enrollment>
  <condition>Covid-19</condition>
  <condition>Pneumonia, Viral</condition>
  <condition>ARDS</condition>
  <condition>ARDS, Human</condition>
  <condition>Sars-CoV2</condition>
  <condition>Coronavirus Infection</condition>
  <condition>Corona Virus Infection</condition>
  <arm_group>
    <arm_group_label>Medical treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with ciclesonide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard Medical Care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclesonide Inhalation Aerosol</intervention_name>
    <description>Ciclesonide 320 µg twice daily for 14 days.</description>
    <arm_group_label>Medical treatment</arm_group_label>
    <other_name>Alvesco</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 to 85 years of age that are hospitalized and require oxygen therapy.

          -  Lab-confirmed (PCR-positive) SARS-CoV-2 infection within &lt;48 h of study enrollment or
             a clinical diagnosis of COVID-19 by the treating physician based on symptoms and
             radiological findings within &lt;48 h of study enrollment.

          -  Willing and able to provide written informed consent.

        Exclusion Criteria:

          -  Patients requiring ≥8 L supplemental oxygen at admission or receiving &gt;50% oxygen with
             nasal high flow therapy.

          -  Patients who are hospitalized for palliative care or who have an expected survival of
             less than 72 h.

          -  Patients with cognitive or physical impairment or insufficient language skills which
             precludes either self-administration of the intervention drug or understanding
             information given about the study.

          -  Ongoing use of corticosteroids, ketokonazol, itrakonazol, ritonavir or nelfinavir.

          -  Pregnant or breastfeeding women.

          -  Women in child-bearing age not using adequate contraceptive methods

          -  History of hypersensitivity to ciclesonide or other substances included in the
             treatment.

          -  Participation in a clinical trial within the past 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel P Andersson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ola Blennow, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Capio S:t Görans Hospital and Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Brodin, MD</last_name>
    <phone>+46736313527</phone>
    <email>daniel.brodin@capiostgoran.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel P Andersson, MD, PhD</last_name>
    <phone>+46704490004</phone>
    <email>daniel.p.andersson@ki.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Danderyd Hospital</name>
      <address>
        <city>Danderyd</city>
        <state>Entrévägen 2</state>
        <zip>18257</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Magnus Bager, MD</last_name>
      <phone>+46812358068</phone>
      <email>magnus.bager@sll.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Capio S:t Görans Hospital</name>
      <address>
        <city>Stockholm</city>
        <state>Sankt Göransplan 1</state>
        <zip>11281</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Daniel Brodin, MD</last_name>
      <phone>+46736313527</phone>
      <email>daniel.brodin@capiostgoran.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Västmanland County Hospital Västerås</name>
      <address>
        <city>Västerås</city>
        <state>Sigtunagatan</state>
        <zip>72189</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Anders Krifors, MD</last_name>
      <email>anders.krifors@regionvastmanland.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Daniel P Andersson, MD, PhD</last_name>
      <email>daniel.p.andersson@ki.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 7, 2020</study_first_submitted>
  <study_first_submitted_qc>May 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <last_update_submitted>May 9, 2020</last_update_submitted>
  <last_update_submitted_qc>May 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>St Goran's Hospital</investigator_affiliation>
    <investigator_full_name>Ola Blennow, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Corona virus</keyword>
  <keyword>Covid-19</keyword>
  <keyword>Sars-CoV2</keyword>
  <keyword>Randomized controlled trial</keyword>
  <keyword>Human</keyword>
  <keyword>Intervention study</keyword>
  <keyword>Corticosteroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Pneumonia, Viral</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciclesonide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

